Want to see HK:8622 full AI Analyst Report?

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

0 Followers

8622 Stock Chart & Stats

HK$0.42

HK$0.01(7.32%)

At close: Jan 09 4:00 PM EST

HK$0.42

HK$0.01(7.32%)

Day’s Range― - ―

52-Week RangeHK$0.15 - HK$0.75

Previous CloseN/A

Volume952.00K

Average Volume (3M)2.14M

Market Cap

HK$91.75M

Enterprise ValueHK$68.87M

Total Cash (Recent Filing)HK$41.96M

Total Debt (Recent Filing)HK$4.96M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Aug 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding515,472,000

10 Day Avg. Volume1,472,000

30 Day Avg. Volume2,141,866

Financial Highlights & Ratios

PEG Ratio-2.40

Price to Book (P/B)3.83

Price to Sales (P/S)6.93

P/FCF Ratio-59.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginA ~63% gross margin signals strong product-level economics and likely pricing power or low variable costs. Over the medium term this margin provides a durable buffer to fund R&D or commercial expansion and offers scope for operating leverage if fixed costs are controlled.

Conservative LeverageDebt-to-equity near 0.10 indicates conservative financial structure, reducing refinancing and interest-rate vulnerability. This persistent balance-sheet flexibility can support short-term funding needs and strategic investments while the business works to stabilize cash flows.

Modest Revenue GrowthConsistent, positive top-line growth demonstrates sustained market demand and commercial traction. Over several quarters this trend can enable scale benefits, help absorb fixed costs, and underpin a path to durable margin improvement if cost structure is aligned with revenue.

Bears Say

Negative Operating & Free Cash FlowTwo consecutive years of negative operating and free cash flow indicate the business is structurally consuming cash, increasing reliance on the balance sheet or external financing. This elevates funding risk and constrains investment, hiring, or R&D over the coming months.

Persistent Losses / Weak MarginsDeep negative operating and net margins show the company has not converted healthy gross profits into operating profitability. Persistent losses erode capital and limit the firm's ability to sustainably fund growth without structural cost reductions or margin recovery.

Declining Equity And Negative ROEFalling equity and a negative return on equity reflect capital erosion from ongoing losses. This structural deterioration reduces financial flexibility, may raise the cost of future capital, and limits long-term strategic options if profitability is not restored.

8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?

Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.15 and its highest was HK$0.75 in the past 12 months.

What is Huakang Biomedical Holdings Company Limited’s market cap?

Huakang Biomedical Holdings Company Limited’s market cap is HK$91.75M.

When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?

Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.

How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?

Huakang Biomedical Holdings Company Limited released its earnings results on Mar 27, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.

Is Huakang Biomedical Holdings Company Limited overvalued?

According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Huakang Biomedical Holdings Company Limited pay dividends?

Huakang Biomedical Holdings Company Limited does not currently pay dividends.

What is Huakang Biomedical Holdings Company Limited’s EPS estimate?

Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Huakang Biomedical Holdings Company Limited have?

Huakang Biomedical Holdings Company Limited has 515,472,000 shares outstanding.

What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?

Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?

Currently, no hedge funds are holding shares in HK:8622

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Huakang Biomedical Holdings Company Limited Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

6.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Huakang Biomedical Holdings Company Limited

Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.